As the next round of the Trans-Pacific Partnership Agreement (TPP) negotiations continues in Malaysia, MSF urges negotiating countries to reject provisions that threaten to restrict access to affordable medicines for millions of people.

More >

NY Times Lettter-to-the-Editor on MSF concerns that a provision in proposed U.S. health care legislation will allow pharmaceutical companies to extend monopolies on high-priced, cutting-edge medicines.

More >

Doctors Without Borders is urging law makers to revise a provision in the U.S. health care legislation that would essentially allow pharmaceutical companies to extend their monopolies on a rapidly expanding and high-priced brand of drugs known as biologics. Biologics--medicines derived from living cells--hold great promise for new vaccines and medicines. Unfortunately, the biologics provision in the current legislation will create a massive barrier to developing generic versions of these cutting-edge drugs.

More >

Statement by Sophie Delaunay Executive Director, MSF-USA

This annual Ministerial review focusing on philanthropy and the Global Health Agenda clearly shows recognition of the urgency to address global health challenges. However, this initiative cannot replace the critical need for greater government leadership to stimulate medical innovation for neglected diseases affecting millions in the poorest corners of the world.

More >

Before the High Level task force communicates its first Comprehensive Framework for Action, Médecins Sans Frontières urges careful consideration of the population that is most vulnerable to the dire consequences of malnutrition – children under two.

More >

My name is Dr. Tido von Schoen-Angerer and I am speaking on behalf of Médecins Sans Frontières. Thank you for the opportunity to address this important gathering.

In 2000, I was working in one of MSF’s AIDS projects. Our response to the pandemic was one based on a simple medical decision: faced with the urgency of patients dying, the only acceptable response was to treat. This was an ethical imperative, to treat, regardless of the difficulties.

More >

U.S congressional briefing delivered by Dr. Buddhima Lokuge, U.S. Manager of MSF's Campaign for Access to Essential Medicines on Thailand's compulsory drug licensing.

More >

Dear Mr. White, We are writing to you to express our concern about the lack of availability in developing countries of the new melt extrusion (Meltrex) formulation of lopinavir/ritonavir (LPV/r), marketed as Kaletra (200/50mg tablets).

More >

Submitted to the Committee on Ways and Means of the House of Representatives

More >

Transcript of an MSF doctor's extemporaneous remarks on Kala Azar in the Sudan before the Congressional Human Rights Caucus and the Congressional Black Caucus Health Brain Trust on access to medicines.

More >

Pages